Researchers say the gut microbiome may be a viable targetable biomarker to improve immunotherapy responses in those with glioblastoma and a range of other cancers.
Researchers say the gut microbiome may be a viable targetable biomarker to improve immunotherapy responses in those with glioblastoma and a range of other cancers.